Zymeworks Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated $27.6 million in revenue from research and development collaborations during the third quarter, marking a 73% increase from $16 million in the same period last year. For the nine months ended September 30, 2025, total revenue reached $103.5 million, a substantial 128% increase compared to $45.3 million for the same period in 2024. This growth was primarily driven by milestone payments, including a notable $25 million from Johnson & Johnson for the advancement of pasritamig into a Phase 3 trial.
Despite the increase in revenue, Zymeworks reported a net loss of $19.6 million for the third quarter, a decrease from a loss of $29.9 million in the prior year. For the nine-month period, the net loss was $39.9 million, down from $99.2 million in 2024. The reduction in losses is attributed to lower operating expenses, which totaled $49.7 million for the quarter, slightly down from $50.2 million a year earlier. The company’s research and development expenses decreased to $35.6 million from $36.4 million, reflecting reduced clinical support costs following the approval of its lead product, zanidatamab.
In terms of strategic developments, Zymeworks has made significant strides in its product pipeline. The company’s lead candidate, zanidatamab, received accelerated approval from the FDA for the treatment of HER2-positive biliary tract cancer, and it has also gained conditional approval in China. The company is actively pursuing additional indications for zanidatamab and has entered into collaborations with BeOne Medicines and Jazz Pharmaceuticals to expand its market reach. Furthermore, Zymeworks announced the initiation of a Phase 1 trial for ZW251, a novel antibody-drug conjugate targeting hepatocellular carcinoma, and presented initial clinical data for ZW191 at a recent conference.
Operationally, Zymeworks has maintained a stable workforce, with 75.1 million shares outstanding as of September 30, 2025, up from 68.9 million at the end of 2024. The company’s cash and cash equivalents stood at $64.8 million, with total assets amounting to $397.3 million. Zymeworks has also been active in its stock repurchase program, having repurchased 1.03 million shares for approximately $15.7 million during the quarter. The company anticipates that its existing cash resources will be sufficient to fund operations for at least the next twelve months.
Looking ahead, Zymeworks remains focused on advancing its clinical programs and expanding its strategic partnerships. The company expects to continue incurring losses as it invests in research and development activities. However, with a robust pipeline and recent regulatory approvals, Zymeworks is positioned to capitalize on future growth opportunities in the biopharmaceutical sector.
About Zymeworks Inc.
Zymeworks Inc. is a biotechnology company specializing in developing multifunctional, antibody-based therapeutics for cancer and autoimmune diseases. Its platforms enable precise engineering of bispecific, multispecific, and antibody-drug conjugates. The company partners globally to advance innovative treatments, leveraging proprietary technologies to address unmet medical needs and generate revenue through licensing, milestone payments, and royalties. Its pipeline includes clinical and preclinical candidates targeting high-value cancer indications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.